94 related articles for article (PubMed ID: 6282231)
21. Serum factors inhibiting E-rosette formation in patients with lung malignancies.
Saiz-Garcia F; Rodriguez-Valverde V
Bull Cancer; 1981; 68(4):346-9. PubMed ID: 6274454
[No Abstract] [Full Text] [Related]
22. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
23. [Circulating immunocomplexes in lung neoplasms].
Pesek M; Sefrna F; Simecek C; Racek J
Vnitr Lek; 1982 Jun; 28(6):571-6. PubMed ID: 6287725
[No Abstract] [Full Text] [Related]
24. [Use of monoclonal antibodies for immunodiagnosis of lung cancer].
Romanova RI; Gergert VI; Filippov VP; Goncharskaia MA; Evgushchenko GV; Sidorova NF; Gorelova LA
Probl Tuberk; 1997; (5):44-8. PubMed ID: 9454255
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
26. [Role of immunotherapy in the combined treatment of lung cancer].
Trapeznikov NN; Gorodilova VV; Babakova SV; Kadagidze ZG; Trakhtenberg AKh
Vopr Onkol; 1982; 28(2):51-6. PubMed ID: 6278769
[No Abstract] [Full Text] [Related]
27. [Anti-tissue autoantibodies in malignant pulmonary neoplasms].
Ruffatti A; Visentin G; Giordano C; Bozzo R; De Silvestro G; Todesco S
Minerva Med; 1983 May; 74(22-23):1319-24. PubMed ID: 6304572
[TBL] [Abstract][Full Text] [Related]
28. Failure of cell-mediated effector mechanisms in lung cancer.
Feo Figarella E; Morillo F; Blanca I; Bianco NE
J Natl Cancer Inst; 1984 Jul; 73(1):1-6. PubMed ID: 6330420
[TBL] [Abstract][Full Text] [Related]
29. Immunoglobulins and complement components in patients with lung cancer.
Oner F; Savaş I; Numanoğlu N
Tuberk Toraks; 2004; 52(1):19-23. PubMed ID: 15143368
[TBL] [Abstract][Full Text] [Related]
30. Isolation, characterization, and biosynthesis of Forssman antigen in human lung and lung carcinoma.
Yoda Y; Ishibashi T; Makita A
J Biochem; 1980 Dec; 88(6):1887-90. PubMed ID: 6257673
[TBL] [Abstract][Full Text] [Related]
31. [Comparing serum tumor antigen detection combined with CT scan with PET-CT for lung cancer diagnosis].
Zhang X; Li TR; Chen ZS; Ouyang XN
Ai Zheng; 2006 Jan; 25(1):66-8. PubMed ID: 16405752
[TBL] [Abstract][Full Text] [Related]
32. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
33. Diminished lymphocyte responses to phytohemagglutinin in lung cancer.
Hadjipetrou-Kourounakis L; Tsougranis A
Biochem Exp Biol; 1980; 16(4):357-64. PubMed ID: 6285942
[TBL] [Abstract][Full Text] [Related]
34. [Immunomorphology of lymph nodes and prognosis in lung cancer].
Di Giorgio A; Sammartino P; Canavese A; Arnone P; Sibio S; Accarpio F; Al Mansour M
Minerva Chir; 2001 Apr; 56(2):153-9. PubMed ID: 11353348
[TBL] [Abstract][Full Text] [Related]
35. BCM-IMx behaviour in patients with lung diseases.
Allende MT; Hernández J; Fernández Fernández M; Fernández Llana B; Suarez B; Ruibal A
Bull Cancer; 1991; 78(9):843-5. PubMed ID: 1661198
[No Abstract] [Full Text] [Related]
36. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of the tuberculin skin test as a parameter of cellular immunocompetence in cancer patients].
Sone S; Ogushi F; Tsubura H; Fukuoka M
Kekkaku; 1983 Oct; 58(10):559-62. PubMed ID: 6319794
[No Abstract] [Full Text] [Related]
38. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
39. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of the immunologic system in patients with small cell and squamous cell lung cancer during the early stage of treatment].
Janicka G; Chyczewska E; Przylipiak M; Kowal E
Pol Tyg Lek; 1985 Aug; 40(34):963-6. PubMed ID: 2999734
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
